AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics reported fiscal Q1 2027 sales of $80.9 million, up 6.9% year over year, led by MedTech revenue growth of 13.2% to $39.9 million; GAAP gross margin expanded 410 bps to 59.4%, including a $1.2 million tariff-refund benefit. Adjusted net loss narrowed to $1.8 million from $4.2 million, and adjusted EBITDA rose to $5.0 million from $2.2 million. Management reiterated FY2027 revenue guidance of $336 million–$341 million and adjusted EBITDA guidance of $13 million–$16 million, while forecasting an adjusted loss per share of $0.29–$0.24 and positive operating cash flow for the full year. CEO James Clemmer will be succeeded by Eric Honroth on Nov. 2, 2026; management also cited dynamic tariff impacts and weaker year-over-year AngioVac revenue as risks.

Analysis

The attractive signal is mix-driven rather than yet an earnings inflection: faster-growing medtech can lift gross margin, but roughly 10% of sales directed to R&D and ongoing operating losses may absorb much of that benefit. The quarter’s 57.8% margin excluding tariff refunds is not a clean run rate when management guides to 54–55% for the year; second-half conversion costs, inflation, mix, or pricing could erase apparent progress. Treat positive full-year operating cash flow as an important execution test, not a given: the $34 million cash balance leaves limited room for repeated seasonal-sized outflows if the expected recovery fails.

Near term, revenue growth and improved adjusted EBITDA support a mildly constructive reaction, but the capital-sales surge in NanoKnife is a weak basis for extrapolation. Disposable growth and procedure use are the better adoption checks. Over 1–3 months, reimbursement expansion and the incoming CEO transition are catalysts; a leadership change can also delay decisions. Over 6–18 months, NanoKnife BPH is optionality only: an IDE approval to study the indication is not evidence of efficacy, durability, reimbursement, or commercial economics. Auryon and AlphaVac gains could pressure incumbent suppliers such as Philips, Penumbra, and Inari Medical/Stryker if share gains persist, but the call provides no independent share data.

Contrarian point: the large BPH market estimate risks anchoring investors to a distant opportunity while near-term cash generation and back-half margins remain the actual valuation gates. Without current price and valuation data, the results do not justify a price-target-based or aggressive event trade.

Key Decisions for Investors

• No aggressive opening trade. Keep ANGO on a watchlist; consider a small, staged long only after the next report confirms continuing NanoKnife disposable/procedure growth and progress toward positive operating cash flow. Avoid using capital placements alone as the entry signal.
• For the next 1–3 months, monitor reimbursement coverage, CEO transition execution, and quarterly cash conversion. Reassess negatively if management withdraws full-year positive operating cash flow expectations or if disposables weaken despite continued system placements.
• Treat BPH as unpriced optionality, not a base-case earnings driver. Revisit only as clinical evidence establishes symptom benefit and durability and the company clarifies the program’s spend and reimbursement pathway.
• Falsifiers for the constructive mix-shift thesis: full-year gross margin falls below the guided 54–55% range, medtech growth decelerates materially, or cash use persists beyond the expected seasonal pattern. No pair or options position is warranted without valuation, liquidity, and current-price data.